These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 34978915)
1. Buprenorphine Microdosing for the Pain and Palliative Care Clinician. Quirk K; Stevenson M J Palliat Med; 2022 Jan; 25(1):145-154. PubMed ID: 34978915 [TBL] [Abstract][Full Text] [Related]
2. Rapid buprenorphine microdosing for opioid use disorder in a hospitalized patient receiving very high doses of full agonist opioids for acute pain management: Titration, implementation barriers, and strategies to overcomes. DeWeese JP; Krenz JR; Wakeman SE; Peckham AM Subst Abus; 2021; 42(4):506-511. PubMed ID: 33945452 [No Abstract] [Full Text] [Related]
3. Buprenorphine Microdosing Cross Tapers: A Time for Change. Raheemullah A; Benhamou OM; Kuo J; Lembke A Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554317 [TBL] [Abstract][Full Text] [Related]
4. Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review. Spreen LA; Dittmar EN; Quirk KC; Smith MA Pharmacotherapy; 2022 May; 42(5):411-427. PubMed ID: 35302671 [TBL] [Abstract][Full Text] [Related]
5. Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series. Martin YN; Deljou A; Weingarten TN; Schroeder DR; Sprung J BMC Anesthesiol; 2019 May; 19(1):68. PubMed ID: 31068127 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C; Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007 [TBL] [Abstract][Full Text] [Related]
7. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
8. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283 [TBL] [Abstract][Full Text] [Related]
9. A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration. Kalluri HV; Zhang H; Caritis SN; Venkataramanan R Br J Clin Pharmacol; 2017 Nov; 83(11):2458-2473. PubMed ID: 28688108 [TBL] [Abstract][Full Text] [Related]
10. Survey of Buprenorphine Low-dose Regimens Used by Healthcare Institutions. Hardy M; Grable S; Otley R; Pershing M J Addict Med; 2023 Sep-Oct 01; 17(5):521-527. PubMed ID: 37788604 [TBL] [Abstract][Full Text] [Related]
11. Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy. Greenwald MK; Comer SD; Fiellin DA Drug Alcohol Depend; 2014 Nov; 144():1-11. PubMed ID: 25179217 [TBL] [Abstract][Full Text] [Related]
12. The switching process from buprenorphine sublingual tablets to the monthly buprenorphine subcutaneous depot injection in opioid dependent patients. Guillery SPE; Reiners S; Fahrner M; Enge S; Hellweg R; Kunte H; Kronenberg G Addict Biol; 2023 May; 28(5):e13275. PubMed ID: 37186443 [TBL] [Abstract][Full Text] [Related]
13. Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol. Terasaki D; Smith C; Calcaterra SL Pharmacotherapy; 2019 Oct; 39(10):1023-1029. PubMed ID: 31348544 [TBL] [Abstract][Full Text] [Related]
14. Perioperative Management of Buprenorphine: Solving the Conundrum. Quaye AN; Zhang Y Pain Med; 2019 Jul; 20(7):1395-1408. PubMed ID: 30500943 [TBL] [Abstract][Full Text] [Related]
15. Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series. Peckham AM; Kehoe LG; Gray JR; Wakeman SE J Subst Abuse Treat; 2021 Jul; 126():108316. PubMed ID: 34116808 [TBL] [Abstract][Full Text] [Related]
16. Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study. Baumgartner K; Salmo E; Liss D; Devgun J; Mullins M; Galati B; Kelly J; Schwarz E Clin Toxicol (Phila); 2022 Jun; 60(6):688-693. PubMed ID: 35048759 [TBL] [Abstract][Full Text] [Related]
17. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315 [TBL] [Abstract][Full Text] [Related]
18. Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial. Seval N; Nunez J; Roth P; Schade M; Strong M; Frank CA; Litwin AH; Levin FR; Brady KT; Nunes EV; Springer SA J Addict Med; 2023 Jul-Aug 01; 17(4):e232-e239. PubMed ID: 37579095 [TBL] [Abstract][Full Text] [Related]